TNFRSF4 and neoplasm: The cellular product in this early-phase study was a third-generation CAR T-cell therapy targeting the mesenchymal tumour antigen disialoganglioside GD2 and co-expressing two co-stimulatory signalling domains (OX40 and 4-1-BB); the lympho-depleting conditioning regimen was cyclophosphamide.